CN103992263A - Donepezil purifying method - Google Patents

Donepezil purifying method Download PDF

Info

Publication number
CN103992263A
CN103992263A CN201410219985.7A CN201410219985A CN103992263A CN 103992263 A CN103992263 A CN 103992263A CN 201410219985 A CN201410219985 A CN 201410219985A CN 103992263 A CN103992263 A CN 103992263A
Authority
CN
China
Prior art keywords
water
acceptable salt
organic phase
organic solvent
pharmacy acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201410219985.7A
Other languages
Chinese (zh)
Other versions
CN103992263B (en
Inventor
陈道新
郭阳志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Hisun Pharmaceutical Co Ltd
Original Assignee
Zhejiang Hisun Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharmaceutical Co Ltd filed Critical Zhejiang Hisun Pharmaceutical Co Ltd
Priority to CN201410219985.7A priority Critical patent/CN103992263B/en
Publication of CN103992263A publication Critical patent/CN103992263A/en
Application granted granted Critical
Publication of CN103992263B publication Critical patent/CN103992263B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Abstract

The invention relates to a purifying method of donepezil or pharmaceutically acceptable salt thereof. The method comprises the following steps: (1) providing a mixture with dissolved donepezil or pharmaceutically acceptable salt thereof, wherein the mixture contains a hydrophobic organic solvent and water; (2) adjusting the pH value of acid or alkali of the mixture in the step (1) to 3-5; (3) separating the organic phase and water phase obtained in the step (2); (4) optionally, extracting the water phase obtained in the step (3) once or repeatedly by use of the hydrophobic organic solvent; (5) combining the organic phases obtained in the steps (3) and (4); (6) separating the organic phase obtained in the step (5) to obtain purified donepezil; (7) optionally, converting the donepezil obtained in the step (6) into pharmaceutically acceptable salt thereof. The method provided by the invention is simple to operate, and the purity and yield of the obtained donepezil are very high, thus the method is very suitable for commercial production.

Description

A kind of purification process of E2020
[technical field]
The invention belongs to medical technical field, be specifically related to a kind of purification process of E2020.
[background technology]
E 2020 is s-generation Pseudocholinesterase (ChE) inhibitor by the research and development of Japanese Wei Cai Pharmaceutical Co., Ltd.The special permission that this product obtains U.S. FDA in November, 1996 is ratified for clinical, commodity are called " Aricept ", and first in the U.S., went on the market in 1997, more than 50 the countries and regions listing in the whole world subsequently, be the leading kind in current global anti-senile dementia disease drug market, the structural formula of E2020 is as follows:
At present, the synthesis technique of E2020 has a lot, and wherein compound (III) is the key intermediate of synthetic E2020:
Chinese Pharmaceutical Journal the 40th the 18th phase of volume of September in 2005, contain honor, Hu Yongzhou in the study on the synthesis > of < < E2020 > mono-literary composition, disclose 5,6-dimethoxy-1-indone (V) and 1-benzyl-4-piperidinealdehyde (IV) are under sodium hydroxide exists, methyl alcohol is made solvent, and under room temperature, the method for compound (III) is prepared in reaction:
Through many experiments, find, synthetic according to the method, can not get pure compound (III), in this reaction process, generated a kind of E2020 hydroxyl impurity (II):
Its content reaches 10-20%.Due to this impurity (II) and compound (III) and E2020 structural similitude, be therefore difficult to remove by the method for recrystallization.
Chinese patent CN200810212668.7 discloses the method for a kind of purified compound (III):
The method is included under the existence of mineral alkali, by compound (III) crude product at C 6-C 12aromatic solvent in reacting by heating, make E2020 hydroxyl impurity (II) change compound (III) into:
But the method need to be reacted under comparatively high temps, but also use the aromatic solvent larger to human injury, be not suitable for commercially producing.
The method of a kind of removal E2020 hydroxyl impurity (II) is disclosed in WO2007108011A,
Comprise: under the existence of sulphonate and organic bases, in certain solvent, E2020 hydroxyl impurity (II) is transformed into compound (III):
In the method, use mixed solvent methylsulfonyl chloride and triethylamine, and methylsulfonyl chloride has stronger tearing property and pungency, toxicity is higher, not only environment is had to harm, increases difficulty, and be unfavorable for commercial operation to the disposal of three wastes.
The disclosed E2020 hydroxyl of prior art impurity (II) although removal method can reduce to a great extent the content of E2020 hydroxyl impurity (II) in finished product, but still can residual a certain amount of E2020 hydroxyl impurity (II) in the E2020 product preparing after these methods are processed, make E2020 quality product be difficult to meet pharmacopoeia of each country standard.Because E2020 hydroxyl impurity (II) and E2020 structure are closely similar, and the removal method about this hydroxyl impurity (II) in E2020 product rarely has report in prior art, therefore, be badly in need of a kind of simple to operate, mild condition, environmental protection, is easy to business-like method and removes the E2020 hydroxyl impurity (II) in E2020 product.
[summary of the invention]
The object of the present invention is to provide the purification process of a kind of E2020 or its pharmacy acceptable salt, described E2020 or its pharmacy acceptable salt contain as shown in the formula the E2020 hydroxyl impurity shown in (II):
The method is simple to operate, and reaction conditions is gentle, is applicable to very much commercially producing.
Concrete scheme of the present invention is as follows:
E2020 shown in purifying formula (I) or a method for its pharmacy acceptable salt,
Wherein said E2020 or its pharmacy acceptable salt contain suc as formula the E2020 hydroxyl impurity shown in (II):
Described method comprises:
(1) provide a kind of mixed solution that is dissolved with E2020 or its pharmacy acceptable salt, in wherein said mixed solution, contain hydrophobic organic solvent and water;
(2) mixed solution of step (1) is used to acid or adjusting PH with base value to 3～5;
(3) separating step (2) gained organic phase and water;
(4) optional, step (3) gained water is extracted to one or many with hydrophobic organic solvent;
(5) combining step (3) and (4) gained organic phase;
(6) the separated E2020 that obtains purifying from step (5) gained organic phase;
(7) optional, step (6) gained E2020 is changed into its pharmacy acceptable salt.
Wherein, the described hydrophobic organic solvent of step (1) is selected from methylene dichloride, ethyl acetate, chloroform, or their mixture.
Wherein, in the mixed solution of step (1), the volume ratio of water and hydrophobic organic solvent has no particular limits, as long as described mixed solution can form the two-phase system of water and organic phase, preferably, the volume ratio of water and hydrophobic organic solvent is 1/2～2:1, more preferably 2/3～1:1.
Wherein, the described acid of step (2) is strong acid, is preferably hydrochloric acid or sulfuric acid, more preferably hydrochloric acid.
Wherein, the described alkali of step (2) is highly basic, is preferably sodium hydroxide or potassium hydroxide.
Wherein, the described pH value of step (2) is 4～5.
In order to improve yield, the water that step (3) separation can be obtained extracts one or many with hydrophobic organic solvent, then merges organic phase.Wherein, the described hydrophobic organic solvent of step (4) is selected from methylene dichloride, ethyl acetate, chloroform, or their mixture.
Wherein, the described E2020 pharmacy acceptable salt of step (7) is preferably E2020 hydrochloride.
Because E2020 hydroxyl impurity (II) is very close with E2020 structure, be difficult to remove this impurity by the method for recrystallization, the present invention, by adjusting the pH value of E2020 solution, then adopts simple solvent-extracted mode, and hydroxyl impurity is separated from finished product, do not need the reactions such as special High Temperature High Pressure, simple to operate, separating effect is better, and environmental pollution is little, be applicable to very much suitability for industrialized production, the E2020 finally obtaining meets standards of pharmacopoeia.
[specific embodiments]
Below by embodiment, the invention will be further described.It should be understood that described in the embodiment of the present invention that preparation method is only used for illustrating the present invention, rather than limitation of the present invention, apply design of the present invention to preparation method's of the present invention simple modifications all in the scope of protection of present invention.
Reagent in following examples is commercially available prod, E2020 and hydrochloride thereof can be according to Chinese Journal of Pharmaceuticals the 36th volume o. 11ths in 2005, the method preparation that He Bingming, Qiu Youchun, Chen Jie, Zhang Fuli record in the synthetic > > of < < E 2020.
Embodiment 1
Get E2020 (HPLC purity 98.66%, wherein contain 1.34% hydroxyl impurity (II)) 5g, add the methylene dichloride of 150ml to be dissolved to clearly, then add the water of 100ml, then use the aqueous hydrochloric acid adjust pH to 4.5 of 1N, stir layering, separated organic phase and water 30 minutes, organic phase is evaporated to dry, obtain the E2020 white solid 3.8g of purifying, its HPLC purity: 99.76%, hydroxyl impurity (II): 0.05%.
Embodiment 2:
Get E2020 (HPLC purity 98.66%, wherein contain 1.34% hydroxyl impurity (II)) 5g, add the acetic acid ethyl dissolution of 150ml to clear, then add the water of 100ml, then use the aqueous hydrochloric acid adjust pH to 4.0 of 1N, stir layering, separated organic phase and water 30 minutes, organic phase is evaporated to dry, obtain the E2020 white solid 3.6g of purifying, its HPLC purity: 99.93%, hydroxyl impurity (II): 0.05%.
Embodiment 3:
(HPLC purity is 98.66% to get E2020, wherein contain 1.34% hydroxyl impurity (II)) 5g, add the methylene dichloride of 150ml to be dissolved to clearly, then the water that adds 100ml, then use the aqueous hydrochloric acid adjust pH to 3.0 of 1N, stir layering, separated organic phase and water 30 minutes, in water, add methylene dichloride 150ml, stir layering, separated organic phase and water 30 minutes, merge organic phase, be evaporated to dryly, obtain the E2020 white solid 3.6g of purifying, its HPLC purity; 99.75%, hydroxyl impurity (II): 0.05%.
Embodiment 4:
(HPLC purity is 98.66% to get E2020, wherein contain 1.34% hydroxyl impurity (II)) 5g, add the methylene dichloride of 150ml to be dissolved to clearly, then the water that adds 100ml, then use the aqueous hydrochloric acid adjust pH to 5.0 of 1N, stir layering, separated organic phase and water 30 minutes, in water, add methylene dichloride 150ml, stir layering, separated organic phase and water 30 minutes, merge organic phase, be evaporated to dryly, obtain the E2020 white solid 4.5g of purifying, its HPLC purity; 99.87%, hydroxyl impurity (II): 0.10%.
Embodiment 5:
(HPLC purity is 98.70% to get E 2020, wherein contain 1.03% hydroxyl impurity (II)) 5g, add the methylene dichloride of 150ml then to add the water of 100ml, stir 30min, dissolve clarification, then use the aqueous sodium hydroxide solution adjust pH to 3.0 of 1N, stir 30 minutes, layering, separated organic phase and water, add methylene dichloride 150ml in water, stir 30 minutes, layering, separated organic phase and water, merge organic phase, is evaporated to dry, obtain the E2020 white solid 3.2g of purifying, its HPLC purity; 99.91%, hydroxyl impurity (II): 0.04%.
Embodiment 6:
(HPLC purity is 98.70% to get E 2020, wherein contain 1.03% hydroxyl impurity (II)) 5g, add the methylene dichloride of 150ml then to add the water of 100ml, stir 30min, dissolve clarification, then use the aqueous sodium hydroxide solution adjust pH to 5.0 of 1N, stir layering 30 minutes, separated organic phase and water, organic phase is evaporated to dry, obtains the E2020 white solid 3.7g of purifying, its HPLC purity; 99.80%, hydroxyl impurity (II): 0.09%.Embodiment 7:
Get E2020 (HPLC purity is 98.66%, wherein contains 1.34% hydroxyl impurity (II)) 5g, add the methylene dichloride of 150ml, stirring and dissolving is clarified, and then adds the water of 100ml, with acetic acid adjust pH to 4.5, stir layering, separated organic phase and water 30 minutes, in water, add methylene dichloride 150ml, stir layering 30 minutes, separated organic phase and water, merge organic phase, is evaporated to dry, obtain the E2020 white solid 4.5g of purifying, its HPLC purity; 99.03%, hydroxyl impurity (II): 0.62%.

Claims (10)

1. a method for the E2020 shown in purifying formula I or its pharmacy acceptable salt,
Wherein said E2020 or its pharmacy acceptable salt contain as shown in the formula the E2020 hydroxyl impurity shown in II:
It is characterized in that, described method comprises:
(1) provide a kind of mixed solution that is dissolved with E2020 or its pharmacy acceptable salt, in wherein said mixed solution, contain hydrophobic organic solvent and water;
(2) mixed solution of step (1) is used to acid or adjusting PH with base value to 3～5;
(3) separating step (2) gained organic phase and water;
(4) optional, step (3) gained water is extracted to one or many with hydrophobic organic solvent;
(5) combining step (3) and (4) gained organic phase;
(6) the separated E2020 that obtains purifying from step (5) gained organic phase;
(7) optional, step (6) gained E2020 is changed into its pharmacy acceptable salt.
2. method according to claim 1, is characterized in that, the described hydrophobic organic solvent of step (1) is selected from methylene dichloride, ethyl acetate, chloroform, or their mixture.
3. method according to claim 1 and 2, is characterized in that, the water that step (1) is described and the volume ratio of hydrophobic organic solvent are 1/2～2:1, preferably 2/3～1:1.
4. according to the method described in claim 1-3 any one, it is characterized in that, the described acid of step (2) is strong acid.
5. method according to claim 4, is characterized in that, described strong acid is selected from hydrochloric acid or sulfuric acid, preferably hydrochloric acid.
6. according to the method described in claim 1-5 any one, it is characterized in that, the described alkali of step (2) is highly basic.
7. method according to claim 6, is characterized in that, described highly basic is selected from sodium hydroxide or potassium hydroxide.
8. according to the method described in claim 1-7 any one, it is characterized in that, the described pH value of step (2) is 4～5.
9. according to the method described in claim 1-8 any one, it is characterized in that, the described hydrophobic organic solvent of step (4) is selected from methylene dichloride, ethyl acetate, chloroform, or their mixture.
10. according to the method described in claim 1-9 any one, it is characterized in that, described E2020 pharmacy acceptable salt is selected from E2020 hydrochloride.
CN201410219985.7A 2014-05-22 2014-05-22 A kind of purification process of E2020 Active CN103992263B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410219985.7A CN103992263B (en) 2014-05-22 2014-05-22 A kind of purification process of E2020

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410219985.7A CN103992263B (en) 2014-05-22 2014-05-22 A kind of purification process of E2020

Publications (2)

Publication Number Publication Date
CN103992263A true CN103992263A (en) 2014-08-20
CN103992263B CN103992263B (en) 2016-02-10

Family

ID=51306631

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410219985.7A Active CN103992263B (en) 2014-05-22 2014-05-22 A kind of purification process of E2020

Country Status (1)

Country Link
CN (1) CN103992263B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107188845A (en) * 2017-05-18 2017-09-22 芜湖耄智生物科技有限公司 The method of purification of Doneppezil Hydrochloride
CN108047131A (en) * 2017-12-08 2018-05-18 重庆植恩药业有限公司 Doneppezil Hydrochloride impurity and its preparation method and application
CN110540520A (en) * 2019-09-12 2019-12-06 威海迪素制药有限公司 Method for purifying donepezil

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007015052A1 (en) * 2005-07-30 2007-02-08 Pliva Istrazivanje I Razvoj D.O.O. Process for the preparation of donepezil and intermediate compounds thereof as well as hydrates of donepezil
WO2007108011A2 (en) * 2006-03-20 2007-09-27 Ind-Swift Laboratories Limited Process for the preparation of highly pure donepezil

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007015052A1 (en) * 2005-07-30 2007-02-08 Pliva Istrazivanje I Razvoj D.O.O. Process for the preparation of donepezil and intermediate compounds thereof as well as hydrates of donepezil
WO2007108011A2 (en) * 2006-03-20 2007-09-27 Ind-Swift Laboratories Limited Process for the preparation of highly pure donepezil

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107188845A (en) * 2017-05-18 2017-09-22 芜湖耄智生物科技有限公司 The method of purification of Doneppezil Hydrochloride
CN108047131A (en) * 2017-12-08 2018-05-18 重庆植恩药业有限公司 Doneppezil Hydrochloride impurity and its preparation method and application
CN110540520A (en) * 2019-09-12 2019-12-06 威海迪素制药有限公司 Method for purifying donepezil
CN110540520B (en) * 2019-09-12 2022-02-08 迪嘉药业集团有限公司 Method for purifying donepezil

Also Published As

Publication number Publication date
CN103992263B (en) 2016-02-10

Similar Documents

Publication Publication Date Title
CN106810426B (en) Method for synthesizing cannabidiol
JP6055183B2 (en) Nalmefene hydrochloride dihydrate
AU2010252392B2 (en) Preparation of nalmefene hydrochloride from naltrexone
ITMI20121344A1 (en) PROCESS OF PREPARATION OF URSODESOSICOLICO ACID WITH HIGH PURITY
RU2006136524A (en) SYNTHESIS OF 2-METHYL-4- (4-METHYL-1-PIPERAZINYL) -1OH-THIENO (2, 3-B) (1,5) BENZODIAZEPINE AND ITS SALTS
CN103992263B (en) A kind of purification process of E2020
JP5166878B2 (en) Method for producing galantamine hydrobromide
CN104447947A (en) Process for producing pidotimod
US7982062B2 (en) Process for the preparation of cholanic acids
US11384116B2 (en) Methods of making cholic acid derivatives and starting materials therefor
CN102911235A (en) Method for producing ursodesoxycholic acid by using chenodeoxycholic acid as raw material
AU730530B2 (en) Tramadol, salts thereof and process for their preparation
EP1966228A1 (en) Purification process for chenodeoxycholic acid
WO2007083908A1 (en) A method for preparing decursinol from angelica gigas with high yield
TW201335110A (en) Process for recovery of nalmefene hydrochloride
CN104703967A (en) Method for purifying fluvoxamine free base and method for preparing highly pure fluvoxamine maleate using same
CN101735296B (en) Method for preparing fludarabine
CN106536468B (en) Preparation method of liquiritigenin precursor
CN105440042B (en) A kind of synthetic method of PP796 intermediates pyrimidine triazole
CN103588700A (en) Method for resolving barnidipine mother nucleus by using glucosamine as resolving agent
CN111607019B (en) Purification method of sugamonic acid
AU2017343384B2 (en) Method for isolation and purification of naltrexone
CN102249847B (en) Method for refining octacosanol
CN103224541B (en) Gemcitabine alpha-isomer conversion recovery process
CN101723959B (en) Method for refining cefbuperazone

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant